Attached files
| file | filename |
|---|---|
| EX-99.1 - Cellectar Biosciences, Inc. | v227294_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM 8-K
___________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: June 28, 2011
(Date of earliest event reported)
NOVELOS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
333-119366
|
04-3321804
|
||
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification Number)
|
One Gateway Center, Suite 504
Newton, MA 02458
(Address of principal executive offices)
(617) 244-1616
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
ITEM 7.01
|
REGULATION FD DISCLOSURE
|
On June 28, 2011, we issued a press release announcing the dismissal of the putative federal securities class action lawsuit against us and Harry S. Palmin, our president and chief executive officer. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference in this Item.
|
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS
|
|
c)
|
Exhibits
|
|
Number
|
Title
|
|
|
99.1
|
Press Release dated June 28, 2011 entitled “Novelos Therapeutics Announces Dismissal of Putative Federal Securities Class Action Lawsuit”
|
|
- 2 -
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: June 28, 2011
|
NOVELOS THERAPEUTICS, INC.
|
||
|
By:
|
/s/ Harry S. Palmin
|
||
|
Harry S. Palmin
|
|||
|
President and Chief Executive Officer
|
|||
- 3 -
EXHIBIT INDEX
|
Number
|
Title
|
|
|
99.1
|
Press Release dated June 28, 2011 entitled “Novelos Therapeutics Announces Dismissal of Putative Federal Securities Class Action Lawsuit”
|
|
- 4 -